[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medication-initiation-for-long-term-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medication-initiation-for-long-term-conditions":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":5},"100595747",false,"NCT07036471","Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland","Evaluation of the myCare Start Service to Support Patients Starting a New Medicine in Switzerland: A Hybrid Type II Effectiveness-implementation Study","myCare Start-I","Patients\n\nInclusion Criteria:\n\n* Must have mandatory basic health insurance in Switzerland\n* Must have been newly prescribed one or more new long-term medications in accordance with the following chronic conditions: cadisovascular diseases (incl. hyertension and thromboprophylaxis), diabetes, hyperlipidemia, depression, respiratory illness (asthma and COPD)\n* Must be able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-\u002Fherself)\n* Must be able to understand language spoken by pharmacy staff and can read and understand study documents (French, German, English)\n* Must understand and are willing to consent to the myCare Start-I study (including the agreement on self-reported questionnaires and collection of health care data via their health insurance company)\n* in the intervention arm, patients must receive the myCare Start service\n\nFor this study, a new medication is a medication that has not been previously dispensed to the patient. This includes one or more new medications for a new diagnosis and or new medications for pre-existing diagnosis of a long-term condition. Included in this working definition:\n\n* The new medication is indicated for one of the five long-term diseases listed above\n* Patient has never had this active ingredient dispensed before (patient still considered eligible if they have received a small initial sample pack from their physician) or restarts an active ingredient after a period of interruption of at least 12 months (time period to be reported by the patient). Please note that for patients, that have already started a sample pack of medication the myCare Start Consultation One can start upon first dispensation at the pharmacy, there is no need to wait 7-14 days.\n* The new active ingredient can be part of a combo preparation (e.g. a diuretic added to an ACE inhibitor into the same preparation)\n* Patient has had no change in active ingredient but has an important change in treatment administration, such as:\n\n  * Change of galenic form (e.g. two different types of inhalators for asthma\u002FCOPD)\n  * Intensification of dosage regiment (e.g. twice a day instead of once a day)\n* The following change is not considered as medication initiation:\n\n  * New dosage of already known active ingredient (e.g. dose escalation of antidepressants)\n  * Simplification of administration mode (e.g. metformin 1000 mg 1-0-0 instead of 500 mg 1-0-1; change in antihypertensive drug regiment in elderly patients having vertigo in the morning: 0-0-X instead of X-0-0)\n\nExclusion Criteria:\n\n* Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients)\n\nPhysicians:\n\nInclusion criteria\n\n\\- Any physician treating a patient for one of the five long-term illnesses listed above is eligible to refer the patient to a pharmacy providing myCare start.\n\nPharmacies:\n\nInclusion criteria:\n\n* Have to be enrolled into the myCare Start service and comply to the requirements of the pharmacy quality system management of having access to a private consultation room or area\n* Must agree to participate in the research study, including the recruitment of control patients and the delivery of the myCare Start service to intervention patients.","ALL","18 Years",{"count":19,"type":20},1600,"ESTIMATED","INTERVENTIONAL",[23],"NA","In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland. A Type II hybrid effectiveness-implementation study will be conducted to evaluate the effectiveness (improvement in adherence), cost-effectiveness and implementation of the service. This evaluation will allow us to build the necessary contextual relevant evidence base to support sustainable funding of the service in the long term.",[26,27,28,29,30,31,32],"Cardio-vascular Disease","Depression Disorders","Diabetes","COPD","Asthma Bronchiale","Hyperlipidaemia","Medication Initiation for Long-term Conditions",[34,35,36,37,38,39,40,41,42,43,44],"patient adherence","medication adherence","medication initiation","long-term treatment","implementation science","interprofessional collaboration","outpatient care","community pharmacy","general practitioner","cost-effectiveness","medication adherence support programme","NOT_YET_RECRUITING","2025-06-16",{"date":48,"type":49},"2025-06-25","ACTUAL",{"date":51,"type":20},"2025-06",{"date":53,"type":20},"2027-01",{"name":55,"class":56},"University of Geneva, Switzerland","OTHER",""]